Patents Assigned to HEFEI COSOURCE PHARMACEUTICAL CO., LTD.
  • Patent number: 10266535
    Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 23, 2019
    Assignees: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.
    Inventors: Jing Liu, Qingsong Liu, Xixiang Li, Aoli Wang, Hong Wu, Cheng Chen, Wenchao Wang, Chen Hu, Zheng Zhao, Jiaxin Wu, Juan Liu, Kailin Yu, Wei Wang, Li Wang, Beilei Wang
  • Publication number: 20180030054
    Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).
    Type: Application
    Filed: August 7, 2015
    Publication date: February 1, 2018
    Applicants: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.
    Inventors: Jing LIU, Qingsong LIU, Xixiang LI, Aoli WANG, Hong WU, Cheng CHEN, Wenchao WANG, Chen HU, Zheng ZHAO, Jiaxin WU, Juan LIU, Kailin YU, Wei WANG, Li WANG, Beilei WANG